Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab deruxtecan master rollover study
jRCT2031230379Recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Dec 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Open-label, single-arm trial of trastuzumab deruxtecan in Nonhematologic neoplasms, sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Treatment-emergent adverse events leading to study drug discontinuation, Treatment-emergent adverse events leading to dose reduction and 2 more. Started Dec 2023; status: recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2031230379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230379.